BioCentury | Sep 20, 2010
Clinical News

Chiroscience regulatory update

...Caesarian section, infiltration shoulder surgery, juvenile epidural surgery, post-operative pain control and cancer pain control. Chiroscience Group plc...
BioCentury | May 24, 2004
Strategy

UCB's transformation

...research is in small molecules, as it acquired these capabilities in its 1999 mergers with Chiroscience Group plc...
BioCentury | May 24, 2004
Strategy

Celltech's path to acquisition

Celltech's path to acquisition Selected events traced against the weekly stock price of Celltech (LSE:CCH; CLL) in pence over the past five years. A.6/15/99Chiroscience merger announced; CCH 6/14/99 Mcap = £364.8M ($591M)B.8/6/99Chiroscience merger completedC.11/11/99Medeva acquisition...
BioCentury | Nov 24, 2003
Finance

Ebb & Flow

...it will close its drug discovery facility in Seattle, which it inherited with the 1999 Chiroscience...
BioCentury | Sep 1, 2003
Strategy

Celltech: Building critical mass

...to increase our critical mass.” Doing that quickly meant making an acquisition, and in 1999 Chiroscience Group plc...
...Cambridge, U.K.) was the logical choice. “British Biotech was already a big problem company. But Chiroscience...
...6/15/99 - Chiroscience merger announcement; CCH 6/14/99 mkt cap = £364.8M ($591M) B. 8/6/99 - Chiroscience...
BioCentury | Aug 4, 2003
Strategy

Bellwether thinking

...an M&A standpoint," he said. CCH reached its current stage of development by merging with Chiroscience Group plc...
BioCentury | Jul 14, 2003
Finance

Ebb & Flow

...also took part in the £331 million ($535 million) merger of Celltech (CCH; CLL) and Chiroscience...
BioCentury | Jul 14, 2003
Strategy

What's in a name?

...U.K.). CCH reached its current market cap of £944 million ($1.6 billion) by merging with Chiroscience Group plc...
BioCentury | May 5, 2003
Company News

Akubio board of directors update

...Akubio Ltd. , Cambridge, U.K. Business: Diagnostics/Imaging Appointed: John Padfield, former CEO of Chiroscience Group plc , as...
BioCentury | Jan 27, 2003
Strategy

CAT-OGS: Making it work

...see BioCentury, Dec. 3, 2001). The deal also bears similarities to the 1999 acquisition of Chiroscience Group plc...
...for £563 million ($912 million) in another stock swap (see BioCentury, Nov. 15, 1999). "The Chiroscience...
...Celltech to acquire Medeva," Scott told BioCentury. "Celltech did not get a lot out of Chiroscience...
Items per page:
1 - 10 of 165
BioCentury | Sep 20, 2010
Clinical News

Chiroscience regulatory update

...Caesarian section, infiltration shoulder surgery, juvenile epidural surgery, post-operative pain control and cancer pain control. Chiroscience Group plc...
BioCentury | May 24, 2004
Strategy

UCB's transformation

...research is in small molecules, as it acquired these capabilities in its 1999 mergers with Chiroscience Group plc...
BioCentury | May 24, 2004
Strategy

Celltech's path to acquisition

Celltech's path to acquisition Selected events traced against the weekly stock price of Celltech (LSE:CCH; CLL) in pence over the past five years. A.6/15/99Chiroscience merger announced; CCH 6/14/99 Mcap = £364.8M ($591M)B.8/6/99Chiroscience merger completedC.11/11/99Medeva acquisition...
BioCentury | Nov 24, 2003
Finance

Ebb & Flow

...it will close its drug discovery facility in Seattle, which it inherited with the 1999 Chiroscience...
BioCentury | Sep 1, 2003
Strategy

Celltech: Building critical mass

...to increase our critical mass.” Doing that quickly meant making an acquisition, and in 1999 Chiroscience Group plc...
...Cambridge, U.K.) was the logical choice. “British Biotech was already a big problem company. But Chiroscience...
...6/15/99 - Chiroscience merger announcement; CCH 6/14/99 mkt cap = £364.8M ($591M) B. 8/6/99 - Chiroscience...
BioCentury | Aug 4, 2003
Strategy

Bellwether thinking

...an M&A standpoint," he said. CCH reached its current stage of development by merging with Chiroscience Group plc...
BioCentury | Jul 14, 2003
Finance

Ebb & Flow

...also took part in the £331 million ($535 million) merger of Celltech (CCH; CLL) and Chiroscience...
BioCentury | Jul 14, 2003
Strategy

What's in a name?

...U.K.). CCH reached its current market cap of £944 million ($1.6 billion) by merging with Chiroscience Group plc...
BioCentury | May 5, 2003
Company News

Akubio board of directors update

...Akubio Ltd. , Cambridge, U.K. Business: Diagnostics/Imaging Appointed: John Padfield, former CEO of Chiroscience Group plc , as...
BioCentury | Jan 27, 2003
Strategy

CAT-OGS: Making it work

...see BioCentury, Dec. 3, 2001). The deal also bears similarities to the 1999 acquisition of Chiroscience Group plc...
...for £563 million ($912 million) in another stock swap (see BioCentury, Nov. 15, 1999). "The Chiroscience...
...Celltech to acquire Medeva," Scott told BioCentury. "Celltech did not get a lot out of Chiroscience...
Items per page:
1 - 10 of 165